In addition to solid tumors, epigenetic drugs (e.g., DNMT inhibitor azacytidine) show clinical benefits in hematologic malignancies, including acute myeloid leukemia (AML) (148, 149). The gene discussed is DNMT1; the disease is acute myeloid leukemia.